{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/whitlow-staphylococcal-herpetic/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"46185de6-35ef-5e34-a1fd-e0d1463c538e","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field d8adc76e-f3ba-4496-a644-1d722421a96f --><h2>Clarithromycin</h2><!-- end field d8adc76e-f3ba-4496-a644-1d722421a96f -->","summary":"","htmlStringContent":"<!-- begin item 3c231a05-6adf-4eff-9923-bd094c7062d0 --><!-- end item 3c231a05-6adf-4eff-9923-bd094c7062d0 -->","topic":{"id":"ac1c1826-f21a-5abd-8e92-1e2db8ea28ea","topicId":"f989f159-ab30-4d16-b9df-b534a9fd4192","topicName":"Whitlow (staphylococcal and herpetic)","slug":"whitlow-staphylococcal-herpetic","lastRevised":"Last revised in January 2021","chapters":[{"id":"8442fc1d-a788-50ac-a15a-9c2c91e8589b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"895f3b40-8720-5843-8910-fe1b288857a8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7e4ec3c7-b080-5717-b1c3-0003acba46e5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7c70fe97-728d-5bc4-94c2-1996b37ee0f9","slug":"changes","fullItemName":"Changes"},{"id":"4889bd92-0b32-558d-8390-80d27fbcce73","slug":"update","fullItemName":"Update"}]},{"id":"1a79ca57-c8cc-5044-ac68-5d220bab1460","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"684fde23-e839-56ff-8b7f-8e6863b2c42d","slug":"goals","fullItemName":"Goals"},{"id":"97b35971-df6d-5ecb-a631-dfcf580e1fa9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12181a78-1b8d-58b4-884a-8930d15cf654","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"521ae353-eea7-5e2f-bd0e-b292540b72eb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"87054726-2905-5ac0-b369-92e5fd68a177","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2b6dffce-588f-532a-9776-7e3ff32005ee","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"2d957194-aa56-5cb7-98aa-cb3d8f988743","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f0191f08-fb2e-5c5b-957c-8a190d5b4539","slug":"definition","fullItemName":"Definition"},{"id":"b8b2a1f1-fbc7-5b8f-a5c4-c0e9409d566f","slug":"causes","fullItemName":"Causes"},{"id":"c7287d38-e377-5d65-9c4f-3201369e0213","slug":"prevalence","fullItemName":"Prevalence"},{"id":"adc749af-b4d0-50c9-9996-b470b8f76613","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d632b72f-6e73-58ee-9d8d-21b6101f6394","slug":"prognosis","fullItemName":"Prognosis"},{"id":"faed0075-1878-5f17-abc9-9316eaa064e7","slug":"complications","fullItemName":"Complications"}]},{"id":"96e4a200-e348-5fab-89e2-f0ba789b7b72","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"910097a7-71be-5c13-949e-0be7c045df35","slug":"diagnosis-of-whitlow","fullItemName":"Diagnosis of whitlow"},{"id":"6f468174-fafe-579c-90f9-500f22e70e17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"8ac8a269-e748-5e7e-9b74-8fb5661d1ae5","fullItemName":"Management","slug":"management","subChapters":[{"id":"ac7fabf7-d7b7-5fb2-a0a6-1d28e040e2c8","slug":"staphylococcal-whitlow","fullItemName":"Scenario: Staphylococcal whitlow"},{"id":"bde8ed40-6fd8-505e-86bb-d75eac34743f","slug":"herpetic-whitlow","fullItemName":"Scenario: Herpetic whitlow"}]},{"id":"5d7afad5-ae43-5c2e-8ecf-6df00603ca01","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3b006b-c4df-5e15-aee8-5ac6c019923f","slug":"aciclovir","fullItemName":"Aciclovir"},{"id":"46185de6-35ef-5e34-a1fd-e0d1463c538e","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"2a50e932-9f92-5a94-a8e5-aab1ee400b9d","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"0ad07f56-519a-59d6-90bc-6b6d6081e6ab","slug":"flucloxacillin","fullItemName":"Flucloxacillin"}]},{"id":"98ea0d83-9b18-58b4-aa73-7a50d72e15ba","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4dd77db6-a4e1-5304-8a06-196e7628f612","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0191f79d-0e03-554c-b0bd-4b592d452f4a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3e95c155-472c-52d0-9098-a797cec2ad27","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f39c5716-7472-576a-be8f-7d705a0dc4dd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"73c24405-a40a-51ba-ac01-8dd957f7c657","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7005b3b9-63e2-5222-840e-73155dac338e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"18dd81bb-78d7-57f1-9fc9-24aa775b3c9d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5d7afad5-ae43-5c2e-8ecf-6df00603ca01","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"070a3a4b-2cc8-51c9-b7da-ee56c3beaf1e","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 2a24103d-cafd-44b3-9355-d1d7d28978cd --><h3>What dose of clarithromycin should I prescribe?</h3><!-- end field 2a24103d-cafd-44b3-9355-d1d7d28978cd -->","summary":"","htmlStringContent":"<!-- begin item 42a2158b-51e7-4827-9781-eaf454f2c00e --><!-- begin field 67f7730c-414c-4957-b82f-000356aefe10 --><ul><li>Clarithromycin doses:</li><ul><li>Adults and children older than 12 years of age — 250 mg to 500 mg (in severe infection), twice daily for 7 days.</li><li>Children 1 month to 12 years of age</li><ul><li>Body weight less than 8 kg — 7.5 mg per kg twice daily.</li><li>Body weight 8–11 kg — 62.5 mg twice daily.</li><li>Body weight 12–19 kg — 125 mg twice daily.</li><li>Body weight 20–29 kg — 187.5 mg twice daily.</li><li>Body weight 30–40 kg — 250 mg twice daily.<br></li></ul></ul></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF for Children, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">PHE, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>]<br></p><!-- end field 67f7730c-414c-4957-b82f-000356aefe10 --><!-- end item 42a2158b-51e7-4827-9781-eaf454f2c00e -->","subChapters":[]},{"id":"42326dd5-d3af-51e7-955d-9723d4672595","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 23016337-e6b1-4d28-89df-bdda02485fa2 --><h3>What are the contraindications and cautions for clarithromycin?</h3><!-- end field 23016337-e6b1-4d28-89df-bdda02485fa2 -->","summary":"","htmlStringContent":"<!-- begin item 5770494c-3e7c-41fd-ab1e-03f432c1fdd5 --><!-- begin field e7420ca1-9165-4d4a-9110-cbcd5b0d11d1 --><ul><li><strong>Do not prescribe clarithromycin</strong> to people with:<ul><li>Known hypersensitivity to clarithromycin or other macrolide antibiotics.</li><li>A history of QT prolongation or ventricular arrhythmia, including Torsade de Pointes.</li><li>Hypokalaemia.</li><li>Severe hepatic failure.</li></ul></li><li>Clarithromycin is also contraindicated for people taking certain <a class=\"topic-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/prescribing-information/clarithromycin/#drug-interactions\">drugs</a>.</li><li><strong>Prescribe clarithromycin with caution</strong> in people with:<ul><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — clarithromycin is principally excreted by the liver. Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with clarithromycin.</li><li>Use half the normal dose in severe renal impairment (eGFR less than 30mL/min) for a maximum duration of 14 days. Avoid Klaricid XL<sup>®</sup>(clarithromycin prolonged release once daily tablets) in people with eGFR less than 30 mL/min.</li><li>Conditions that predispose to QT interval prolongation, such as electrolyte disturbances and people taking drugs that prolong the QT interval  — macrolides can also prolong the QT interval, increasing the risk of Torsades de Pointes arrhythmia. </li><li>Myasthenia gravis — macrolide antibiotics may aggravate weakness symptoms of people with myasthenia gravis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>]</p><!-- end field e7420ca1-9165-4d4a-9110-cbcd5b0d11d1 --><!-- end item 5770494c-3e7c-41fd-ab1e-03f432c1fdd5 -->","subChapters":[]},{"id":"662a8011-2432-5834-9dd7-6623aef4933d","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a67b5750-d243-412e-813d-dba267650dde --><h3>What are the adverse effects of clarithromycin?</h3><!-- end field a67b5750-d243-412e-813d-dba267650dde -->","summary":"","htmlStringContent":"<!-- begin item 6bf3a52c-b9fb-41c3-9f70-d72d8e057d04 --><!-- begin field 09a2787a-3dfd-44d9-ae76-9fbe653a7634 --><ul><li>Clarithromycin is generally well tolerated. </li><li>The most common adverse effects are gastrointestinal — such as nausea, vomiting, dyspepsia, and diarrhoea.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with clarithromycin.</li><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Less common adverse effects include rash and hepatoxicity.</li><li>Very rarely, QT prolongation, ventricular tachycardia, and Torsade de Pointes arrhythmia have been reported.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>]</p><!-- end field 09a2787a-3dfd-44d9-ae76-9fbe653a7634 --><!-- end item 6bf3a52c-b9fb-41c3-9f70-d72d8e057d04 -->","subChapters":[]},{"id":"71fa37ee-920b-5529-b326-ec553569a2c3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 143875c3-8417-47a9-95bd-6b40813d13a8 --><h3>What are the important drug interactions with clarithromycin?</h3><!-- end field 143875c3-8417-47a9-95bd-6b40813d13a8 -->","summary":"","htmlStringContent":"<!-- begin item ea1e2165-29e2-4ccc-8e74-7ed28984a5ea --><!-- begin field 0a8106af-d3f0-4728-a464-743372183fb1 --><ul><li><strong>Drug interactions with clarithromycin include:</strong><ul><li><strong>Pimozide </strong><strong>—</strong> do not prescribe with clarithromycin as concurrent use may result in QT prolongation, cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes.</li><li><strong>Ergotamine and dihydroergotamine</strong> <strong>—</strong> do not prescribe with clarithromycin as concurrent use may result in acute ergot toxicity. </li><li><strong>Colchicine </strong><strong>—</strong> avoid concomitant administration.</li><li><strong>Carbamazepine</strong> <strong>—</strong> monitor carbamazepine levels within 3–5 days of starting clarithromycin, and adjust dose accordingly. Clarithromycin can increase carbamazepine levels, causing carbamazepine toxicity (may present as nausea and vomiting, ataxia, and drowsiness).</li><li><strong>Other drugs that prolong the QT interval</strong> <strong>—</strong> if possible, avoid giving clarithromycin to a person who is already taking a drug that can potentially prolong the QT interval.</li><li><strong>Statins</strong> <strong>—</strong> there is an increased risk of myopathy.<ul><li>For simvastatin — do not prescribe clarithromycin to a person taking simvastatin. Consider temporarily stopping simvastatin during short-term treatment with clarithromycin. </li><li>For atorvastatin — avoid concurrent use with clarithromycin if possible. Consider temporarily stopping atorvastatin during short-term treatment with clarithromycin. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>For pravastatin — prescribe clarithromycin with caution and advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>Other statins — clinically significant interaction with clarithromycin is not expected for rosuvastatin and fluvastatin. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.<strong> </strong></li></ul></li><li><strong>Warfarin</strong> <strong>—</strong> increase monitoring of the international normalized ratio (INR) when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. Clarithromycin may enhance the effect of warfarin. </li><li><strong>Oral hypoglycaemic drugs and insulin</strong> <strong>—</strong> the concurrent use of clarithromycin and antidiabetic drugs (such as sulphonylureas and/or insulin) can result in significant hypoglycaemia.<ul><li>Monitor blood glucose levels more regularly and adjust the antidiabetic drug (and/or insulin) dose accordingly. </li></ul></li><li><strong>Calcium channel blockers (CCBs)</strong> <strong>—</strong> due to an increased risk of hypotension, caution is advised with the concurrent use of clarithromycin and CCBs metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.</li><li><strong>Oral hormonal contraception</strong> <strong>—</strong> additional contraceptive precautions are not required during or after courses of clarithromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">FSRH, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whitlow-staphylococcal-herpetic/references/\">BNF 71, 2016</a>]</p><!-- end field 0a8106af-d3f0-4728-a464-743372183fb1 --><!-- end item ea1e2165-29e2-4ccc-8e74-7ed28984a5ea -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}